Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation |
| |
Authors: | Jean Herman MD Peter Vandenberghe MD PhD Ingeborg van den Heuvel MD Johan Van Cleemput MD PhD Veronique Winnepenninckx MD Rita Van Damme-Lombaerts MD PhD |
| |
Institution: | Department of Pediatric Transplantation, University Hospital Gasthuisberg, Kuleuven University, 49 Herestraat, 3000 Leuven, Belgium. jean.herman@uz.kuleuven.ac.be |
| |
Abstract: | Post-transplantation lymphoproliferative disorders (PTLDs) are life-threatening complications. We report the case of a 7-year-old girl in whom a lymphoproliferative disorder developed more than 2 years after cardiac transplantation. The patient was taking ganciclovir for Epstein-Barr virus hepatitis at the time the PTLD occurred. Rituximab, an anti-CD20 monoclonal antibody, given in the presence of reduced immunosuppression therapy, resulted in a complete response of the PTLD. The Epstein-Barr viral load in the peripheral blood, which was extremely high at diagnosis, dropped promptly and remained below the detection threshold 11 months after completion of therapy. We observed complete depletion of B lymphocytes until 7 months after rituximab therapy, which was associated with an important decrease in immunoglobulin levels. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|